Key facts
- FELIQS’s last known valuation is $16.4M (Oct 2025).
- It has raised $11.8M; the latest was Later Stage VC ($9.6M) in Oct 2025.
- Notable investors include Mitsubishi UFJ Capital, FFG Venture Business Partners, Beyond Next Ventures, Keio Innovation Initiative, Institute for the Global Entrepreneur — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for FELIQS
- ·The full record, as it builds
Funding rounds
No funding rounds for FELIQS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FELIQS
Developer of clinical-stage ophthalmology therapeutics designed to treat major ocular diseases. The company offers a pipeline with orphan and expedited regulatory designations, as well as novel programs addressing retinopathy of prematurity, dry age-related macular degeneration, and recurrent pterygium, enabling patients with serious eye conditions to have improved access to targeted treatments and better clinical outcomes.
- Sector
- Healthcare
- HQ
- Kurume, Japan
- Founded
- 2019
- Employees
- 5
- Website
- feliqs.com/
- Ownership
- Privately Held (backing)
FELIQS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FELIQS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FELIQS in its N-PORT filings yet. We sweep new filings monthly.